Compare Illumina, Inc. (ILMN) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Las Vegas Sands Corp. — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Las Vegas Sands Corp. trades at $36.17 (market cap $23.38B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Las Vegas Sands Corp. for 72 Days on average.
| ILMN | LVS | |
|---|---|---|
Market Cap | $39.95B | $23.38B |
Volume | 3,169,503 | 6,994,661 |
Sector | Health | Consumer Cyclical |
52-Week High | $293.69 | $69.49 |
52-Week Low | $91.00 | $35.81 |
Typical Hold Time | 83 Days | 72 Days |
Enterprise Value | $41.31B | $35.27B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
LVS trades at $36.10, up 0.81% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Fundamentally, the company shows strong profitability with a 12.59% net margin and consistent revenue growth, reaching $13.02B in 2025. Recent earnings have been mixed, with a Q2 2026 miss after two prior beats. Analyst sentiment remains positive with a 59% buy rating and a $59.78 consensus price target, implying significant upside. The company maintains robust cash flow from operations of $3.02B in 2025.
The outlook for LVS is cautiously optimistic, driven by solid fundamentals and analyst confidence, but weighed by technical weakness and high debt levels. Investment opportunity lies in the substantial discount to price targets, while risks include leverage, Macao regulatory exposure, and volatile earnings. The stock's current valuation multiples, such as a P/E of 13.99, appear attractive if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
